Tuberculosis (TB) is a major issue in global health and affects millions of people each year. Multidrug-resistant tuberculosis (MDR-TB) annually causes many deaths worldwide. Development of a way to diagnose and treat patients with MDR-TB can potentially reduce the incidence of the disease. The current study reviews the risk factors, pattern of progression, mechanism of resistance, and interaction between bacteria and the host immune system, which disrupts the immune response. It also targets the components of Mycobacterium tuberculosis (Mtb) and diagnosis and treatment options that could be available for clinical use in the near future. Mutations play an important role in development of MDR-TB and the selection of appropriate mutations can help to understand the type of resistance in patients to anti-TB drugs. In this way, they can be initially treated with proper and effective therapeutic choices, which can accelerate the course of treatment and improve patient health. Targeting the components and enzymes of Mtb is necessary for understanding bacterial survival and finding a way to destroy the pathogen and allow patients to recover faster and prevent the spread of disease, especially resistant strains.
NarenderM., UmasankarK., MalathiJ., ReddyA.R., UmadeviK., DusthackeerA., and RaoK.V.. 2016. Synthesis, in vitro antimycobacterial evaluation and docking studies of some new 5, 6, 7, 8-tetrahydropyrido [4′, 3′: 4, 5] thieno [2, 3-d] pyrimidin-4 (3H)-one schiff bases. Bioorg. Med. Chem. Lett. 26:836–840.
3.
HaoX., YaoL., SunH., LiuY., and TangS.. 2014. A cohort study on the outcome of multidrug-resistant tuberculosis in elderly patients. Zhonghua Jie He He Hu Xi Za Zhi, 37:188–191.
4.
ShinS.S., ModongoC., NcubeR., SepakoE., KlausnerJ.D., and ZetolaN.M.. 2014. Advanced immune suppression is associated with increased prevalence of mixed-strain Mycobacterium tuberculosis infections among persons at high risk for drug-resistant tuberculosis in Botswana. J. Infect. Dis. 211:347–351.
5.
Pedro HdaS., NardiS.M., PereiraM.I., OliveiraR.S., SuffysP.N., GomesH.M., FinardiA.J., MoraesE.B., BaptistaI.M., MachadoR.L., and CastiglioniL.. 2015. Clinical and epidemiological profiles of individuals with drug-resistant tuberculosis. Mem. Inst. Oswaldo Cruz, 110:235–248.
6.
GargR.K., JainA., MalhotraH.S., AgrawalA., and GargR.. 2013. Drug-resistant tuberculous meningitis. Expert Rev. Anti Infect. Ther. 11:605–621.
7.
Chung-DelgadoK., Guillen-BravoS., Revilla-MontagA., and Bernabe-OrtizA.. 2015. Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS One, 10:e0119332.
8.
Gómez-GómezA., Magaña-AquinoM., López-MezaS., Aranda-ÁlvarezM., Díaz-OrnelasD.E., Hernández-SeguraM.G., Salazar-LezamaM.Á., Castellanos-JoyaM., and NoyolaD.E.. 2015. Diabetes and other risk factors for multi-drug resistant tuberculosis in a Mexican population with pulmonary tuberculosis: case control study. Arch. Med. Res. 46:142–148.
9.
MehtaS., YuE.A., AhamedS.F., BonamW., and KennethJ.. 2015. Rifampin resistance and diabetes mellitus in a cross-sectional study of adult patients in rural South India. BMC Infect. Dis. 15:451.
10.
PodewilsL., HoltzT., RiekstinaV., SkripconokaV., ZarovskaE., KirvelaiteG., KreigereE., and LeimaneV.. 2011. Impact of malnutrition on clinical presentation, clinical course, and mortality in MDR-TB patients. Epidemiol. Infect. 139:113–120.
11.
SchnippelK., ShearerK., EvansD., BerhanuR., and NdjekaN.. 2015. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register. Int. J. Infect. Dis. 39:89–94.
12.
VerdugoD., FallowsD., AhujaS., SchlugerN., KreiswirthB., and MathemaB.. 2015. Epidemiologic correlates of pyrazinamide resistant Mycobacterium tuberculosis in New York City. Antimicrob. Agents Chemother. 59:6140–6150.
13.
SrivastavaS., AyyagariA., DholeT., KrishnaniN., NyatiK., and DwivediS.. 2008. Progression of chronic pulmonary tuberculosis in mice intravenously infected with ethambutol resistant Mycobacterium tuberculosis. Indian J. Med. Microbiol. 26:342–348.
14.
BhushanB., ChanderR., KajalN., RangaV., GuptaA., and BhartiH.. 2014. Profile of adverse drug reactions in drug resistant tuberculosis from Punjab. Indian J. Tuberc. 61:318–324.
15.
CoxH., RammaL., WilkinsonL., AzevedoV., and SinanovicE.. 2015. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa. Trop. Med. Int. Health, 20:1337–1345.
16.
BarreraE., LivchitsV., and NardellE.. 2015. FAST: a refocused, intensified, administrative tuberculosis transmission control strategy. Int. J. Tuberc. Lung Dis. 19:381–384.
17.
WivaggC.N., BhattacharyyaR.P., and HungD.T.. 2014. Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis. J. Antibiot. (Tokyo), 67:645–654.
YuenC.M., JenkinsH.E., RodriguezC.A., KeshavjeeS., and BecerraM.C.. 2015. Global and regional burden of isoniazid-resistant tuberculosis. Pediatrics, 136:e50–e59.
20.
KimS.W., HasanuzzamanM., ChoM., HeoY.R., RyuM.-J., HaN.-Y., ParkH.J., ParkH.-Y., and ShinJ.-G.. 2015. CK2-mediated phosphorylation of Hsp90β as a novel mechanism of rifampin-induced MDR1 expression. J. Biol. Chem. 290:17029–17040.
21.
MeftahiN., NamouchiA., MhenniB., BrandisG., HughesD., and MardassiH.. 2015. Evidence for the critical role of a secondary site rpoB mutation in the compensatory evolution and successful transmission of an MDR tuberculosis outbreak strain. J. Antimicrob. Chemother. 71:324–332.
22.
ZhengC., LiS., LuoZ., PiR., SunH., HeQ., TangK., LuoM., LiY., and CouvinD.. 2015. Mixed infections and rifampin hetero-resistance of Mycobacterium tuberculosis clinical isolates. J. Clin. Microbiol. 53:2138–2147.
23.
Rodríguez-CastilloJ.A., Arce-MendozaA.Y., Quintanilla-SillerA., RendonA., Salinas-CarmonaM.C., and Rosas-TaracoA.G.. 2015. Possible association of rare polymorphism in the ABCB1 gene with rifampin and ethambutol drug-resistant tuberculosis. Tuberculosis, 95:532–537.
24.
Cuevas-CórdobaB., EusebioD.M.J., Almaraz-VelazcoR., Muñiz-SalazarR., Laniado-LaborinR., and Zenteno-CuevasR.. 2015. Mutation at embB 306, a potential marker for the identification of multidrug resistance associated with ethambutol in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59:5455–5462.
25.
ArjomandzadeganM., NazariR., ZolfaghariM., TaherahmadiM., SadrniaM., TitovL., AhmadiA., and ShojapoorM.. 2015. Performance assessment of the polymerase chain reaction-restriction fragment length polymorphism method for rapid detection of susceptibility to ethambutol and molecular prediction of extensively drug-resistant tuberculosis in clinical isolates of Mycobacterium tuberculosis. West Indian Med. J. 64:325–332.
26.
RigoutsL., CoeckN., GumusbogaM., de RijkW., AungK., HossainM., FissetteK., RiederH., MeehanC., and de JongB.. 2015. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J. Antimicrob. Chemother. 71:314–323.
27.
FarhatM.R., JacobsonK.R., FrankeM.F., KaurD., SloutskyA., MitnickC.D., and MurrayM.. 2016. Gyrase mutations are associated with variable levels of fluoroquinolone resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 54:727–733.
28.
AkhmetovaA., KozhamkulovU., BismildaV., ChingissovaL., AbildaevT., DymovaM., FilipenkoM., and RamanculovE.. 2015. Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan. Int. J. Tuberc. Lung Dis. 19:179–184.
29.
Alame-EmaneA.K., XuP., Pierre-AudigierC., Cadet-DanielV., ShenX., SraouiaM., SiawayaJ., TakiffH., GaoQ., and GicquelB.. 2015. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance. Int. J. Tuberc. Lung Dis. 19:679–684.
30.
GuY., YuX., JiangG., WangX., MaY., LiY., and HuangH.. 2016. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations. Diagn. Microbiol. Infect. Dis. 84:207–211.
31.
PandeyB., GroverS., TyagiC., GoyalS., JamalS., SinghA., KaurJ., and GroverA.. 2016. Molecular principles behind pyrazinamide resistance due to mutations in panD gene in Mycobacterium tuberculosis. Gene, 581:31–42.
32.
ArjomandzadeganM., and GravandS.. 2015. Analysis of rpsL and rrs genes mutations related to streptomycin resistance in MDR and XDR clinical isolates of Mycobacterium tuberculosis. Tuberk. Toraks, 63:235–242.
33.
SunH., ZhangC., XiangL., PiR., GuoZ., ZhengC., LiS., ZhaoY., TangK., and LuoM.. 2016. Characterization of mutations in streptomycin-resistant Mycobacterium tuberculosis isolates in Sichuan, China and the association between Beijing-lineage and dual-mutation in gidB. Tuberculosis, 96:102–106.
34.
RajuA., KulkarniS., RayM., RajanM., and DeganiM.S.. 2015. E84G mutation in dihydrofolate reductase from drug resistant strains of Mycobacterium tuberculosis (Mumbai, India) leads to increased interaction with Trimethoprim. Int. J. Mycobacteriol. 4:97–103.
35.
ZhangS., ChenJ., CuiP., ShiW., ZhangW., and ZhangY.. 2015. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 70:2507–2510.
36.
SmithK.L.J., SainiD., BardarovS., LarsenM., FrothinghamR., GandhiN.R., JacobsW.R.Jr., SturmA.W., and LeeS.. 2014. Reduced virulence of an extensively drug-resistant outbreak strain of Mycobacterium tuberculosis in a murine model. PLoS One, 9:e94953.
37.
BhatterP., ChatterjeeA., and MistryN.. 2014. Kinetics of recA and recX induction in drug-susceptible and MDR clinical strains of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 69:3199–3202.
38.
MishraR., ShuklaP., HuangW., and HuN.. 2015. Gene mutations in Mycobacterium tuberculosis: multidrug-resistant TB as an emerging global public health crisis. Tuberculosis, 95:1–5.
39.
MoreiraW., AzizD.B., and DickT.. 2016. Boromycin kills mycobacterial persisters without detectable resistance. Front. Microbiol. 7:199.
40.
JacksonM., McNeilM.R., and BrennanP.J.. 2013. Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis. Future Microbiol. 8:855–875.
41.
TahlanK., WilsonR., KastrinskyD.B., AroraK., NairV., FischerE., BarnesS.W., WalkerJ.R., AllandD., and BarryC.E.. 2012. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56:1797–1809.
42.
LiW., UpadhyayA., FontesF.L., NorthE.J., WangY., CransD.C., GrzegorzewiczA.E., JonesV., FranzblauS.G., and LeeR.E.. 2014. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 4;58:6413–6423.
43.
PieroniM., MachadoD., AzzaliE., Santos CostaS., CoutoI., CostantinoG., and ViveirosM.. 2015. Rational design and synthesis of thioridazine analogues as enhancers of the antituberculosis therapy. J. Med. Chem. 58:5842–5853.
44.
WerngrenJ., WijkanderM., PerskvistN., SubramarianB., SambandamurthyV.K., RodriguesC., and HoffnerS.. 2014. In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58:4222–4223.
45.
WarrierT., TropisM., WerngrenJ., DiehlA., GengenbacherM., SchlegelB., SchadeM., OschkinatH., DaffeM., and HoffnerS.. 2012. Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis. Antimicrob. Agents Chemother. 56:1735–1743.
46.
ChipmanD., BarakZ., and SchlossJ.V.. 1998. Biosynthesis of 2-aceto-2-hydroxy acids: acetolactate synthases and acetohydroxyacid synthases. Biochim. Biophys. Acta, 1385:401–419.
47.
ChipmanD.M., DugglebyR.G., and TittmannK.. 2005. Mechanisms of acetohydroxyacid synthases. Curr. Opin. Chem. Biol. 9:475–481.
48.
BaigI.A., MoonJ.-Y., LeeS.-C., RyooS.-W., and YoonM.-Y.. 2015. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase. Biochim. Biophys. Acta, 1854:1338–1350.
49.
OngC.W., ElkingtonP.T., and FriedlandJ.S.. 2014. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 190:9–18.
50.
RaniC., and KhanI.A.. 2016. UDP-GlcNAc pathway: potential target for inhibitor discovery against M. tuberculosis. Eur. J. Pharm. Sci. 83:62–70.
51.
RajputV.S., MehraR., KumarS., NargotraA., SinghP.P., and KhanI.A.. 2016. Screening of antitubercular compound library identifies novel shikimate kinase inhibitors of Mycobacterium tuberculosis. Appl. Microbiol. Biotechnol. 100:5415–5426.
52.
KrátkýM., VinšováJ., NovotnáE., MandíkováJ., WsólV., TrejtnarF., UlmannV., StolaříkováJ., FernandesS., and BhatS.. 2012. Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase. Tuberculosis, 92:434–439.
53.
KrátkýM., VinšováJ., NovotnáE., and StolaříkováJ.. 2014. Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase. Eur. J. Pharm. Sci. 53:1–9.
54.
PaldeP.B., BhaskarA., Pedró RosaL.E., MadouxF., ChaseP., GuptaV., SpicerT., ScampaviaL., SinghA., and CarrollK.S.. 2015. First-in-class inhibitors of sulfur metabolism with bactericidal activity against non-replicating M. tuberculosis. ACS Chem. Biol. 11:172–184.
55.
WangX., TangX., ZhouZ., and HuangQ.. 2018. Histone deacetylase 6 inhibitor enhances resistance to Mycobacterium tuberculosis infection through innate and adaptive immunity in mice. Pathog. Dis. 76:fty064.
56.
KatariaA., SinghJ., and KunduB.. 2019. Identification and validation of l-asparaginase as a potential metabolic target against Mycobacterium tuberculosis. J. Cell. Biochem. 120:143–154.
57.
MoreiraW., SanthanakrishnanS., NganG.J., LowC.B., SangthongpitagK., PoulsenA., DymockB.W., and DickT.. 2017. Towards selective mycobacterial ClpP1P2 inhibitors with reduced activity against the human proteasome. Antimicrob. Agents Chemother. 61:e02307–e02316.
58.
AmbadyA., AwasthyD., YadavR., BasuthkarS., SeshadriK., and SharmaU.. 2012. Evaluation of CoA biosynthesis proteins of Mycobacterium tuberculosis as potential drug targets. Tuberculosis, 92:521–528.
59.
HajianB., ScoccheraE., KeshipeddyS., NarendranG., ShoenC., KrucinskaJ., ReeveS., CynamonM., AndersonA.C., and WrightD.L.. 2016. Propargyl-linked antifolates are potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. PLoS One, 11:e0161740.
RiouC., GrayC.M., LugongoloM., GwalaT., KiravuA., DenisoP., Stewart-IsherwoodL., OmarS.V., GrobuschM.P., and CoetzeeG.. 2014. A subset of circulating blood mycobacteria-specific CD4 T cells can predict the time to Mycobacterium tuberculosis sputum culture conversion. PLoS One, 9:e102178.
62.
ParkS.-K., HongS., EumS.-Y., LeeI.H., ShinD.O., ChoJ.E., ChoS., and ChoS.-N.. 2011. Changes in cell-mediated immune response after lung resection surgery for MDR-TB patients. Tuberculosis, 91:300–307.
63.
LuJ., YeS., QinR., DengY., and LiC.-P.. 2013. Effect of Chinese herbal medicine extracts on cell-mediated immunity in a rat model of tuberculosis induced by multiple drug-resistant bacilli. Mol. Med. Rep. 8:227–232.
64.
Sada-OvalleI., Torre-BouscouletL., Valdez-VázquezR., and LascurainR.. 2009. In vitro cytotoxicity of CD8+ T cells in multi-drug-resistant tuberculosis. A preliminary report. Respirology, 14:574–578.
65.
GeffnerL., YokoboriN., BasileJ., SchierlohP., BalboaL., RomeroM.M., RitaccoV., VescovoM., MontanerP.G., and LopezB.. 2009. Patients with multidrug-resistant tuberculosis display impaired Th1 responses and enhanced regulatory T-cell levels in response to an outbreak of multidrug-resistant Mycobacterium tuberculosis M and Ra strains. Infect. Immun. 77:5025–5034.
66.
BasileJ.I., GeffnerL.J., RomeroM.M., BalboaL., Sabio y GarcíaC., RitaccoV., GarcíaA., CuffréM., AbbateE., and LópezB.. 2011. Outbreaks of Mycobacterium tuberculosis MDR strains induce high IL-17 T-cell response in patients with MDR tuberculosis that is closely associated with high antigen load. J. Infect. Dis. 204:1054–1064.
67.
ChenC.Y., YaoS., HuangD., WeiH., SicardH., ZengG., JomaaH., LarsenM.H., JacobsW.R.Jr., and WangR.. 2013. Phosphoantigen/IL2 expansion and differentiation of Vγ2Vδ2 T cells increase resistance to tuberculosis in nonhuman primates. PLoS Pathog. 9:e1003501.
68.
HuS., DuX., HuangY., FuY., YangY., ZhanX., HeW., WenQ., ZhouX., and ZhouC.. 2018. NLRC3 negatively regulates CD4+ T cells and impacts protective immunity during Mycobacterium tuberculosis infection. PLoS Pathog. 14:e1007266.
69.
WuY.E., PengW.G., CaiY.M., ZhengG.Z., ZhengG.L., LinJ.H., ZhangS.W., and LiK.. 2010. Decrease in CD4+ CD25+ FoxP3+ Treg cells after pulmonary resection in the treatment of cavity multidrug-resistant tuberculosis. Int. J. Infect. Dis. 14:e815–e822.
70.
WuY.E., DuZ.R., CaiY.M., PengW.G., ZhengG.Z., ZhengG.L., WuL.B., and LiK.. 2015. Effective expansion of forkhead box P3+ regulatory T cells via early secreted antigenic target 6 and antigen 85 complex B from Mycobacterium tuberculosis. Mol. Med. Rep., 11:3134–3142.
71.
SinghA., DeyA.B., MohanA., SharmaP.K., and MitraD.K.. 2012. Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-γ producing T cells. PLoS One, 7:e44728.
72.
PinheiroR.O., de OliveiraE.B., Dos SantosG., Sperandio da SilvaG., de Andrade SilvaB., TelesR., MilagresA., SarnoE., DalcolmoM., and SampaioE.. 2013. Different immunosuppressive mechanisms in multi-drug-resistant tuberculosis and non-tuberculous mycobacteria patients. Clin. Exp. Immunol. 171:210–219.
73.
AbreuM.T., CarvalheiroH., Rodrigues-SousaT., DomingosA., Segorbe-LuisA., Rodrigues-SantosP., and Souto-CarneiroM.M.. 2014. Alterations in the peripheral blood B cell subpopulations of multidrug-resistant tuberculosis patients. Clin. Exp. Med. 14:423–429.
74.
SchierlohP., KleppL., VazquezC., RochaR.V., BlancoF.C., BalboaL., LópezB., RitaccoV., BigiF., and Sasiain MdelC.. 2014. Differential expression of immunogenic proteins on virulent Mycobacterium tuberculosis clinical isolates. Biomed Res. Int. 2014:741309.
75.
OkadaM., and KitaY.. 2010. Anti-tuberculosis immunity by cytotoxic T cells* granulysin and the development of novel vaccines (HSP-65 DNA+ IL-12 DNA). Kekkaku, 85:531–538.
76.
OkadaM., KitaY., NakajimaT., HashimotoS., NakataniH., NishimatsuS., NishidaY., KanamaruN., KanedaY., and TakamoriY.. 2013. The study of novel DNA vaccines against tuberculosis: induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis. Hum Vaccin. Immunother. 9:515–525.
77.
BertholetS., IretonG.C., OrdwayD.J., WindishH.P., PineS.O., KahnM., PhanT., OrmeI.M., VedvickT.S., and BaldwinS.L.. 2010. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci. Transl. Med. 2:53ra74.
78.
ShenH., WangC., YangE., XuY., LiuW., YanJ., WangF., and WangH.. 2010. Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-α induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice. Microbiol. Immunol. 54:435–441.
79.
MaJ., TianM., FanX., YuQ., JingY., WangW., LiL., and ZhouZ.. 2016. Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre-and post-exposure infections by driving Th1-type T cell immunity. Oncotarget, 7:63804–63815.
80.
ShinuP., SinghV., and NairA.. 2016. Isoniazid and rifampin drug susceptibility testing: application of 2,3,5-triphenyl tetrazolium chloride assay and microscopic-observation drug-susceptibility assay directly on Ziehl-Neelsen smear positive sputum specimens. Braz. J. Infect. Dis. 20:33–40.
81.
JunillonT., VimontA., MosticoneD., MallenB., BarilF., RozandC., and FlandroisJ.-P.. 2012. Simplified detection of food-borne pathogens: an in situ high affinity capture and staining concept. J. Microbiol. Methods, 91:501–505.
82.
WangX., PappoeF., HuangY., ChengX., XuD., WangH., and XuY.. 2015. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in children: a meta-analysis. Clin. Lab. 61:1775–1785.
CobanA.Y., DeveciA., SunterA.T., PalominoJ.C., and MartinA.. 2014. Resazurin microtiter assay for isoniazid, rifampicin, ethambutol and streptomycin resistance detection in Mycobacterium tuberculosis: updated meta-analysis. Int. J. Mycobacteriol. 3:230–241.
85.
PalominoJ.-C., MartinA., CamachoM., GuerraH., SwingsJ., and PortaelsF.. 2002. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:2720–2722.
86.
LiH., ZhouL., LuoJ., YuJ., YangH., and WeiH.. 2016. Rapid colorimetric pyrazinamide susceptibility testing of Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 20:462–467.
87.
AkinedenÖ., WeirichS., AbdulmawjoodA., FailingK., and BülteM.. 2015. Application of a fluorescence microscopy technique for detecting viable Mycobacterium avium ssp. paratuberculosis cells in milk. Food Anal. Methods, 8:499–506.
88.
IchijoT., IzumiY., NakamotoS., YamaguchiN., and NasuM.. 2014. Distribution and respiratory activity of mycobacteria in household water system of healthy volunteers in Japan. PLoS One, 9:e110554.
89.
MaslovD.A., ZaľchikovaM.V., ChernousovaL.N., ShurK.V., BekkerO.B., SmirnovaT.G., LarionovaE.E., AndreevskayaS.N., ZhangY., and DanilenkoV.N.. 2015. Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: pncA sequencing versus Bactec MGIT 960. Tuberculosis, 95:608–612.
90.
ChengS.-J., ThibertL., SanchezT., HeifetsL., and ZhangY.. 2000. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob. Agents Chemother. 44:528–532.
91.
AhmadS., MokaddasE., and JaberA.-A.. 2004. Rapid detection of ethambutol-resistant Mycobacterium tuberculosis strains by PCR-RFLP targeting embB codons 306 and 497 and iniA codon 501 mutations. Mol. Cell. Probes, 18:299–306.
92.
KaushikA., MakkarN., PandeyP., ParrishN., SinghU., and LamichhaneG.. 2015. Carbapenems and rifampin exhibit synergy against. Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59:6561–6567.
93.
HugonnetJ.-E., and BlanchardJ.S.. 2007. Irreversible inhibition of the Mycobacterium tuberculosis β-lactamase by clavulanate. Biochemistry, 46:11998–12004.
94.
van RijnS.P., van AltenaR., AkkermanO.W., van SoolingenD., van der LaanT., de LangeW.C., KosterinkJ.G., van der WerfT.S., and AlffenaarJ.-W.C.. 2016. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. Eur. Respir. J. 47:1229–1234.
95.
FoxG.J., OxladeO., and MenziesD.. 2015. Fluoroquinolone therapy for the prevention of multidrug-resistant tuberculosis in contacts. A cost-effectiveness analysis. Am. J. Respir. Crit. Care Med. 192:229–237.
96.
LeeH., JeongB.-H., ParkH.Y., JeonK., HuhH.J., LeeN.Y., and KohW.-J.. 2016. Treatment outcomes with fluoroquinolone-containing regimens for isoniazid-resistant pulmonary tuberculosis. Antimicrob. Agents Chemother. 60:471–477.
97.
FàbregaA., MadurgaS., GiraltE., and VilaJ.. 2009. Mechanism of action of and resistance to quinolones. Microb. Biotechnol. 2:40–61.
98.
LeechawengwongsM., PrammanananT., JaitrongS., BillamasP., MakhaoN., ThamnongdeeN., ThanormchatA., PhurattanakornkulA., RattanarangseeS., RatanajarayaC., DisratthakitA., and ChaiprasertA.. 2018. In vitro activity and mic of sitafloxacin against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis isolated in Thailand. Antimicrob. Agents Chemother. 62:e00825-17.
99.
BonnetM., BastardM., Du CrosP., KhamraevA., KimenyeK., KhurkhumalS., HayrapetyanA., ThembaD., TelnovA., and Sanchez-PadillaE.. 2016. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int. J. Tuberc. Lung Dis. 20:177–186.
100.
StinsonK., KurepinaN., VenterA., FujiwaraM., KawasakiM., TimmJ., ShashkinaE., KreiswirthB.N., LiuY., and MatsumotoM.. 2016. Minimum inhibitory concentration of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration. Antimicrob. Agents Chemother. 60:3316–3322.
101.
DiaconA.H., PymA., GrobuschM., PatientiaR., RustomjeeR., Page-ShippL., PistoriusC., KrauseR., BogoshiM., and ChurchyardG.. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360:2397–2405.
102.
NdjekaN., ConradieF., SchnippelK., HughesJ., BantubaniN., FerreiraH., MaartensG., MametjaD., MeintjesG., and PadanilamX.. 2015. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int. J. Tuberc. Lung Dis. 19:979–985.
103.
Al MahmudH., SeoH., KimS., IslamM.I., NamK.-W., ChoH.-D., and SongH.-Y.. 2017. Thymoquinone (TQ) inhibits the replication of intracellular Mycobacterium tuberculosis in macrophages and modulates nitric oxide production. BMC Complement. Altern. Med. 17:279.
104.
JangW.S., KimS., PodderB., JyotiM.A., NamK.-W., LeeB.-E., and SongH.-Y.. 2015. Anti-mycobacterial activity of Tamoxifen against drug-resistant and intra-macrophage Mycobacterium tuberculosis. J. Microbiol. Biotechnol. 25:946–950.
105.
SharmaV., SharmaS., Hoener zu BentrupK., McKinneyJ.D., RussellD.G., JacobsW.R.Jr., and SacchettiniJ.C.. 2000. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat. Struct. Mol. Biol. 7:663.
106.
LuJ., YueJ., WuJ., LuoR., HuZ., LiJ., BaiY., TangZ., XianQ., and ZhangX.. 2010. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis. Pharmacology, 85:365–371.
107.
LanY., LamJ.T., SiuG.K., YamW.C., MasonA.J., and LamJ.K.. 2014. Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis. Tuberculosis, 94:678–689.
108.
HungA.W., SilvestreH.L., WenS., CiulliA., BlundellT.L., and AbellC.. 2009. Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew. Chem. Int. Ed. Engl., 48:8452–8456.
109.
PetheK., BifaniP., JangJ., KangS., ParkS., AhnS., JiricekJ., JungJ., JeonH.K., and CechettoJ.. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19:1157.
110.
AbrahamsK.A., CoxJ.A., SpiveyV.L., LomanN.J., PallenM.J., ConstantinidouC., FernandezR., AlemparteC., RemuinanM.J., and BarrosD.. 2012. Identification of novel imidazo [1, 2-a] pyridine inhibitors targeting M. tuberculosis QcrB. PLoS One, 7:e52951.
111.
KangS., KimR.Y., SeoM.J., LeeS., KimY.M., SeoM., SeoJ.J., KoY., ChoiI., and JangJ.. 2014. Lead optimization of a novel series of imidazo [1, 2-a] pyridine amides leading to a clinical candidate (Q203) as a multi-and extensively-drug-resistant anti-tuberculosis agent. J. Med. Chem. 57:5293–5305.
112.
ShenH., WangF., ZengG., ShenL., ChengH., HuangD., WangR., RongL., and ChenZ.W.. 2016. Bis-biguanide dihydrochloride inhibits intracellular replication of M. tuberculosis and controls infection in mice. Sci. Rep. 6:32725.
113.
MansourS.C., de la Fuente-NúñezC., and HancockR.E.. 2015. Peptide IDR-1018: modulating the immune system and targeting bacterial biofilms to treat antibiotic-resistant bacterial infections. J. Pept. Sci. 21:323–329.
114.
Rivas-SantiagoB., Castañeda-DelgadoJ.E., SantiagoC.E.R., WaldbrookM., González-CurielI., León-ContrerasJ.C., Enciso-MorenoJ.A., del VillarV., Mendez-RamosJ., and HancockR.E.. 2013. Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against Mycobacterium tuberculosis infections in animal models. PLoS One, 8:e59119.
115.
SullivanT., and AmorY.B.. 2016. Global introduction of new multidrug-resistant tuberculosis drugs—Balancing regulation with urgent patient needs. Emerg. Infect. Dis. 22:e151228.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
